

## Movement Disorders: Ingrezza

### Member Information

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

### Prescriber Information

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

### Drug Information

1. Drug Name: \_\_\_\_\_ 2. Strength: \_\_\_\_\_ 3. Quantity Per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in Days): Initial Request:  up to 30 Days  60 Days  90 Days  120 Days  180 Days  
Continuation Request:  up to 30 Days  60 Days  90 Days  120 Days  180 Days  365 Days

### Clinical Information

1. Does the member have a diagnosis of moderate to severe Tardive Dyskinesia?  **Yes**  **No**
2. Is the member age 18 or older?  **Yes**  **No**
3. Has the provider completed baseline evaluations of the condition using either Abnormal Involuntary Movement Scale (AIMS) or Extrapyrimalidal Symptom Rating Scale (ESRI) along with this request?  **Yes**  **No**
4. Has the member had a previous trial of an alternative method to manage the condition?  **Yes**  **No**
5. Is the member receiving dual therapy with other vesicular monoamine transporter 2 (VMAT2) inhibitors?  **Yes**  **No**
6. Is the member concurrently using a MAOI (monoamine oxidase inhibitor) or reserpine?  **Yes**  **No**

**\*\* For Continuation of Therapy: answer questions 1-6 and attach documentation that indicates the member has had an improvement in their symptoms from baseline. \*\***

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.